Periodic Reporting for period 1 - ADAMO Robot (The future of precise personalised robotic physiotherapy)
Reporting period: 2019-12-01 to 2020-03-31
Musculoskeletal disorders affect 1.3 billion people worldwide and are the leading cause of disability. Currently, the treatment consists of a manual examination of so-called trigger points (muscle knots responsible for the pain) by a physiotherapist. Consequently, a pressure is applied to each identified trigger point. This state-of-art treatment require manual repetitive effort, is time demanding, costly and depends on the capability of the physiotherapist. As a result, there are long waiting times to receive treatment together with elevated healthcare cost. To address this problem, we have developed a fully automated physiotherapy robot, ADAMO RobotTM, that delivers treatment by applying compressed air.
The current prototype (Version 1) requires the physiotherapist to configure and monitor the treatment. We have evaluated the technical, commercial and financial feasibility of the development of a Version 2.5 of ADAMO RobotTM that will be able to work fully autonomously without the supervision of a physiotherapist. In order to develop Artificial Intelligence (AI) engine capable of predicting and evaluating the treatment, we will use data generated by the Version 1 (commercialized from Q4 2020). We predict to sell 21 units of Version 1 and complete at least 500 treatments before the end of 2021. We have identified all relevant external partners. Moreover, we have evaluated our IP strategy and identified regulatory requirements. Our commercialization strategy is based on direct sales to already established partners, such as physiotherapy clinics, hospitals and insurance companies. Additionally, we will collaborate with marketing and distribution partners to expand within EU and internationally. We have evaluated technical and commercial risks and proposed mitigation measures. ADAMO RobotTM will become profitable already the third year on the market (2022) with a cumulative profit of €7.59 million over the next five years. Additionally, it is estimated that at least 8 new jobs will be created before the 5th year on the market.
ADAMO RobotTM is the first fully automated unmanned physiotherapy robot that uses AI to predict and evaluate the treatment. By the application of AI, the best approach for each individual patient is established based on results of hundreds of completed treatments. Generated medical data are securely stored in a distributed cloud system allowing full treatment track for patients anywhere in the world.